# Brian Lestini

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/brian-lestini/

## Facts

| Field | Value |
| --- | --- |
| Citations | 13,169 |
| Field | Melanoma and MAPK Pathways |
| h-index | 19 |
| i10-index | 22 |
| OpenAlex ID | https://openalex.org/A5075574557 |
| Works | 82 |

## Researcher papers

- [Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-squamous-cell-non-small-cell-lung-cancer/)
- [Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial](https://scholariq.org/papers/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for/)
- [<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors](https://scholariq.org/papers/i-ras-i-mutations-in-cutaneous-squamous-cell-carcinomas-in-patients-treated-with/)
- [Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists](https://scholariq.org/papers/mcl1-downregulation-sensitizes-neuroblastoma-to-cytotoxic-chemotherapy-and-small/)

## Researcher topics

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Mechanisms and Therapy](https://scholariq.org/topics/cancer-mechanisms-and-therapy/)
- [Protein Kinase Regulation and GTPase Signaling](https://scholariq.org/topics/protein-kinase-regulation-and-gtpase-signaling/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.